Global healthcare company Novo Nordisk A/S (CPH:NOVOB) announced on Monday that it has reached a settlement with Teva Pharmaceuticals USA Inc (Teva) on the US patent litigation case for Victoza (liraglutide).
As a result of this settlement, Teva is licensed to launch a generic version of Victoza as of 22 December 2023.
Under certain circumstances, Teva could launch a generic version of Victoza earlier, but not before 22 March 2023, unless the Victoza patents are no longer in force or there is another generic version of Victoza® on the market.
In the event that Novo Nordisk is granted six months paediatric extension for Victoza, all these above-mentioned timelines will be extended by six months.
All other terms of the agreement are confidential.
This agreement is subject to review by the US Federal Trade Commission and the US Department of Justice.
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)